163 related articles for article (PubMed ID: 35847864)
1. Whole-Genome DNA Methylation Sequencing Reveals Epigenetic Changes in Myelodysplastic Syndromes.
Zhou JD; Xu ZJ; Jin Y; Zhang XL; Gu Y; Ma JC; Wen XM; Lin J; Zhang TJ; Qian J
Front Oncol; 2022; 12():897898. PubMed ID: 35847864
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes.
Zhou JD; Zhang TJ; Xu ZJ; Deng ZQ; Gu Y; Ma JC; Wen XM; Leng JY; Lin J; Chen SN; Qian J
Cell Death Dis; 2020 Nov; 11(11):997. PubMed ID: 33219204
[TBL] [Abstract][Full Text] [Related]
3. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of prognosis-related DLX5 methylation as an epigenetic driver in myeloid neoplasms.
Zhang TJ; Xu ZJ; Gu Y; Wen XM; Ma JC; Zhang W; Deng ZQ; Leng JY; Qian J; Lin J; Zhou JD
Clin Transl Med; 2020 Jun; 10(2):e29. PubMed ID: 32508046
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia.
Zhang TJ; Xu ZJ; Gu Y; Ma JC; Wen XM; Zhang W; Deng ZQ; Qian J; Lin J; Zhou JD
Clin Epigenetics; 2021 Jan; 13(1):16. PubMed ID: 33485366
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Yao DM; Ma JC; Wen XM; Guo H; Lin J; Qian J
Clin Chem Lab Med; 2016 May; 54(5):865-71. PubMed ID: 26485746
[TBL] [Abstract][Full Text] [Related]
7. Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome.
Zhou QB; Liu ZT; Wang HZ; Guo XQ; Xu YG; Hu XM
Drug Des Devel Ther; 2020; 14():1641-1650. PubMed ID: 32431489
[TBL] [Abstract][Full Text] [Related]
8. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
del Rey M; O'Hagan K; Dellett M; Aibar S; Colyer HA; Alonso ME; Díez-Campelo M; Armstrong RN; Sharpe DJ; Gutiérrez NC; García JL; De Las Rivas J; Mills KI; Hernández-Rivas JM
Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic changes in FOXO3 and CHEK2 genes and their correlation with clinicopathological findings in myelodysplastic syndromes.
Sharifi MJ; Zaker F; Nasiri N; Yaghmaie M
Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):214-219. PubMed ID: 32217071
[TBL] [Abstract][Full Text] [Related]
11. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression.
Zhao X; Yang F; Li S; Liu M; Ying S; Jia X; Wang X
Br J Haematol; 2014 Jun; 165(5):649-58. PubMed ID: 24601943
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation analysis in myelodysplastic syndromes: diagnostic & prognostic implication.
Solomon PR; Munirajan AK; Tsuchida N; Muthukumarasamy K; Rathinavel A; Selvam GS; Shanmugam G
Indian J Med Res; 2008 Jan; 127(1):52-7. PubMed ID: 18316853
[TBL] [Abstract][Full Text] [Related]
14. [Whole genome methylation profiles of myelodysplastic syndrome and its diagnostic value].
Zhao X; Wang X; Li S; Li N; Ma Y; Lin G
Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):944-8. PubMed ID: 25339336
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.
Kang H; Wang X; Gao L; Cen J; Li M; Wang W; Wang N; Li Y; Wang L; Yu L
Eur J Med Res; 2015 Feb; 20(1):16. PubMed ID: 25889027
[TBL] [Abstract][Full Text] [Related]
16. Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.
Zhao Y; Fei C; Zhang X; Zhang Y; Guo J; Gu S; Li X; Chang C
Tumour Biol; 2013 Feb; 34(1):165-72. PubMed ID: 23055192
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
Shen L; Kantarjian H; Guo Y; Lin E; Shan J; Huang X; Berry D; Ahmed S; Zhu W; Pierce S; Kondo Y; Oki Y; Jelinek J; Saba H; Estey E; Issa JP
J Clin Oncol; 2010 Feb; 28(4):605-13. PubMed ID: 20038729
[TBL] [Abstract][Full Text] [Related]
18. [Study of aberrant p73 promoter methylation in patients with myelodysplastic syndrome].
Zhao YS; Yang R; Gu SC; Guo J; Zhang X; Wu LY; Li X; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):847-51. PubMed ID: 23384909
[TBL] [Abstract][Full Text] [Related]
19. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.
Wang H; Fan R; Wang XQ; Wu DP; Lin GW; Xu Y; Li WY
Ann Hematol; 2013 Jan; 92(2):199-209. PubMed ID: 23093371
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
